New discoveries in progressive myoclonus epilepsies: a clinical outlook

References

• Berkovic SF, Andermann F, Carpenter S, et al. Progressive myoclonus epilepsies: specific causes and diagnosis. N Engl J Med. 1986;315:296–305.
   PubMed Web of Science ®Google Scholar
• Franceschetti S, Michelucci R, Canafoglia L, et al. Progressive myoclonic epilepsies definitive and still undetermined causes. Neurology. 2014;82:405–411.
   PubMed Web of Science ®Google Scholar
• Minassian BA, Striano P, Avanzini G. Progressive myoclonus epilepsies: state of the art. Vol. 30. John Libbey Eurotext. Montrouge, France; 2017.
   Google Scholar
• Tassinari CA, Rubboli G, Shibasaki H. Neurophysiology of positive and negative myoclonus. Electroencephalogr Clin Neurophysiol. 1998;107:181–195.
   PubMedGoogle Scholar
• Damiano JA, Afawi Z, Bahlo M, et al. Mutation of the nuclear lamin gene LMNB2 in progressive myoclonus epilepsy with early ataxia. Hum Mol Genet. 2015;24:4483–4490.
   PubMed Web of Science ®Google Scholar
• Muona M, Berkovic SF, Dibbens LM, et al. A recurrent de novo mutation in KCNC1 causes progressive myoclonus epilepsy. Nat Genet. 2015;47:39–46.
   PubMed Web of Science ®Google Scholar
• Oliver KL, Franceschetti S, Milligan CJ, et al. Myoclonus epilepsy and ataxia due to KCNC1 mutation: analysis of 20 cases and K+ channel properties. Annals of Neurology. 2017;81:677–689.
   PubMed Web of Science ®Google Scholar
• Vilchez D, Ros S, Cifuentes D, et al. Mechanism suppressing glycogen synthesis in neurons and its demise in progressive myoclonus epilepsy. Nat. Neurosci. 2007;10:1407–1413.
   PubMed Web of Science ®Google Scholar
• Valles-Ortega J, Duran J, GarciaRocha M, et al. Neurodegeneration and functional impairments associated with glycogen synthase accumulation in a mouse model of Lafora disease. EMBO Mol Med. 2011;3:667–681.
   PubMed Web of Science ®Google Scholar
• Genton P. Unverricht-Lundborg disease (PME1). Rev Neurol (Paris). 2006;162:819–826.
   PubMed Web of Science ®Google Scholar
• Unverricht H. Die Myoclonie. Leipzig, Vienna: Franz Deuticke; 1891.
   Google Scholar
• Lundborg H. Die progressive myoclonusepilepsie (Unverrichts myoklonie). Uppsala: Almqvist and Wiskell; 1903.
   Google Scholar
• Pennachio LA, Lehesjoki AE, Stone NE, et al. Mutations in the gene encoding cystatin B in progressive myoclonus epilepsy. Science. 1996;271:1731–1734.
   PubMed Web of Science ®Google Scholar
• Virtaneva K, D’Amato E, Miao J, et al. Unstable minisatellite expansion causing recessively inherited myoclonus epilepsy, EPM1. Nat Genet. 1997;15:393–396.
   PubMed Web of Science ®Google Scholar
• Lalioti MD, Scott HS, Buresi C, et al. Dodecamer repeat expansion in cystatin B gene in progressive myoclonus epilepsy. Nature. 1997;386:847–851.
   PubMed Web of Science ®Google Scholar
• Turk V, Bode W. The cystatins: protein inhibitors of cysteine proteinases. FEBS Lett. 1991;285:213–219.
   PubMed Web of Science ®Google Scholar
• Koskenkorva P, Hyppönen J, Äikiä M, et al. Severer phenotype in Unverricht-Lundborg disease (EPM1) patients compound heterozygous for the dodecamer repeat expansion and the c.202C>T mutation in the CSTB gene. Neurodegener Dis. 2011;8:515–522.
   PubMed Web of Science ®Google Scholar
• Lehesjoki AE, Kälviäinen R. “Unverricht-Lundborg disease. In: Pagon RA, Adam MP, Ardinger HH, et al. eds. GeneReviews (Internet). Seattle: University of Washington; 2004 Jun 24 [Updated 2014 Nov 26]. p. 1993–2018.
   Google Scholar
• Assenza G, Benvenga A, Gennaro E, et al. A novel c132-134del mutation in Unverricht-Lundborg disease and the review of literature of heterozygous compound patients. Epilepsia. 2017;58:e31–e35.
   PubMed Web of Science ®Google Scholar
• Berkovic SF, Mazarib A, Walid S, et al. A new clinical and molecular form of Unverricht-Lundborg disease localized by homozygosity mapping. Brain. 2005;128:652–658.
   PubMed Web of Science ®Google Scholar
• Hyppönen J, Äikiä M, Joensuu T, et al. Refining the phenotype of Unverricht-Lundborg disease (EPM1) A population-wide Finnish study. Neurology. 2015;84:1529–1536.
   PubMed Web of Science ®Google Scholar
• Pennacchio LA, Bouley DM, Higgins KM, et al. Progressive ataxia, myoclonic epilepsy and cerebellar apoptosis in cystatin B-deficient mice. Nat Genet. 1998;20:251–258.
   PubMed Web of Science ®Google Scholar
• Shannon P, Pennacchio LA, Houseweart MK, et al. Neuropathological changes in a mouse model of progressive myoclonus epilepsy: cystatin B deficiency and Unverricht-Lundborg disease. J Neuropathol Exp Neurol. 2002;61:1085–1091.
   PubMed Web of Science ®Google Scholar
• Lehtinen MK, Tegelberg S, Schipper H, et al. Cystatin B deficiency sensitizes neurons to oxidative stress in progressive myoclonus epilepsy, EPM1. J Neurosci. 2009;29:5910–5915.
   PubMed Web of Science ®Google Scholar
• Rinne R, Saukko P, Jarvinen M, et al. Reduced cystatin B activity correlates with enhanced cathepsin activity in progressive myoclonus epilepsy. Ann Med. 2002;34:380–385.
   PubMed Web of Science ®Google Scholar
• Crespel A, Ferlazzo E, Franceschetti S, et al. Unverricht‐Lundborg disease. Epileptic Disorders. 2016;18:S28–S37.
   PubMed Web of Science ®Google Scholar
• Kopra O, Joensuu T, Lehesjoki AE. Mouse model of Unverricht-Lundborg disease. Mov disord genetics and models. Second ed. Mark LeDoux: Academic Press, Elsevier Inc; 2015. p. 671–679.
   Google Scholar
• Cohen NR, Hammans SR, Macpherson J, et al. New neuropathological findings in Unverricht–lundborg disease: neuronal intranuclear and cytoplasmic inclusions. Acta Neuropathol. 2011;121:421–427.
   PubMed Web of Science ®Google Scholar
• Delgado-Escueta AV, Ganesh S, Yamakawa K. Advances in the genetics of progressive myoclonus epilepsy. Am J Med Genet. 2001;106:129–138.
   PubMed Web of Science ®Google Scholar
• Lafora GR, Glueck B. Contribution to the histopathology and pathogenesis of myoclonic epilepsy. Bull Gov Hosp Insane. 1911;3:96–111.
   Google Scholar
• Singh S, Ganesh S. Lafora progressive myoclonus epilepsy: a meta-analysis of reported mutations in the first decade following the discovery of the EPM2A and NHLRC1 genes. Hum Mutat. 2009;30:715–723.
   PubMed Web of Science ®Google Scholar
• Serratosa JM, Delgado-Escueta AV, Posada I, et al. The gene for progressive myoclonus epilepsy of the Lafora type maps to chromosome 6q. Hum Mol Genet. 1995;4:1657–1663.
   PubMed Web of Science ®Google Scholar
• Minassian BA, Lee JR, Herbrick JA, et al. Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy. Nat Genet. 1998;20:171–174.
   PubMed Web of Science ®Google Scholar
• Ganesh S, Agarwala KL, Ueda K, et al. Laforin, defective in the progressive myoclonus epilepsy of Lafora type, is a dual-specificity phosphatase associated with polyribosomes. Hum Mol Genet. 2000;9:2251–2261.
   PubMed Web of Science ®Google Scholar
• Chan EM, Young EJ, Ianzano L, et al. Mutations in NHLRC1 cause progressive myoclonus epilepsy. Nat Genet. 2003;35:125–127.
   PubMed Web of Science ®Google Scholar
• Gentry MS, Worby CA, Dixon JE. Insights into lafora disease: malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin. Proc Natl Acad Sci. 2005;102:8501–8506.
   PubMed Web of Science ®Google Scholar
• Chan EM, Omer S, Ahmed M, et al. Progressive myoclonus epilepsy with polyglucosans (Lafora disease): evidence for a third locus. Neurology. 2004;63:565–567.
   PubMed Web of Science ®Google Scholar
• Turnbull J, Girard JM, Lohi H, et al. Early-onset Lafora body disease. Brain. 2012;135:2684–2698.
   PubMed Web of Science ®Google Scholar
• Inoue M, Iwai R, Yamanishi E, et al. Deletion of Prdm8 impairs development of upper-layer neocortical neurons. Genes Cells. 2015;20:758–770.
   PubMed Web of Science ®Google Scholar
• Turnbull J, Tiberia E, Striano P, et al. Lafora disease. Epileptic Disord. 2016;18:38–62.
   PubMed Web of Science ®Google Scholar
• Minassian BA, Ianzano L, Meloche M, et al. Mutation spectrum and predicted function of laforin in Lafora’s progressive myoclonus epilepsy. Neurology. 2000;55:341–346.
   PubMed Web of Science ®Google Scholar
• Guerrero R, Vernia S, Sanz R, et al. A PTG variant contributes to a milder phenotype in Lafora disease. PLoS One. 2011;6:e21294.
   PubMed Web of Science ®Google Scholar
• Wang JY, Stuckey JA, Wishart MJ, et al. A unique carbohydrate binding domain targets the lafora disease phosphatase to glycogen. J Biol Chem. 2002;277:2377–2380.
   PubMed Web of Science ®Google Scholar
• Gayarre J, Duran-Trio L, Garcia OC, et al. The phosphatase activity of laforin is dispensable to rescue Epm2a-/- mice from lafora disease. Brain. 2014;137:806–818.
   PubMed Web of Science ®Google Scholar
• Garyali P, Siwach P, Singh PK, et al. The malin–laforin complex suppresses the cellular toxicity of misfolded proteins by promoting their degradation through the ubiquitin–proteasome system. Hum Mol Genet. 2008;18:688–700.
   PubMed Web of Science ®Google Scholar
• Turnbull J, DePaoli-Roach AA, Zhao XC, et al. PTG depletion removes lafora bodies and rescues the fatal epilepsy of lafora disease. PLoS Genet. 2011;7:e1002037.
   PubMed Web of Science ®Google Scholar
• Turnbull J, Epp JR, Goldsmith D, et al. PTG protein depletion rescues malin-deficient lafora disease in mouse. Ann Neurol. 2014;75:442–446.
   PubMed Web of Science ®Google Scholar
• Duran J, Gruart A, Garcia-Rocha M, et al. Glycogen accumulation underlies neurodegeneration and autophagy impairment in lafora disease. Hum Mol Genet. 2014;23:3147–3156.
   PubMed Web of Science ®Google Scholar
• Puri R, Suzuki T, Yamakawa K, et al. Hyperphosphorylation and aggregation of Tau in laforin-deficient mice, an animal model for Lafora disease. J Biol Chem. 2009;284:22657–22663.
   PubMed Web of Science ®Google Scholar
• Sengupta S, Badhwar I, Upadhyay M, et al. Malin and laforin are essential components of a protein complex that protects cells from thermal stress. J Cell Sci. 2011;124:2277–2286.
   PubMed Web of Science ®Google Scholar
• Garyali P, Segvich DM, DePaoli-Roach AA, et al. Protein degradation and quality control in cells from laforin and malin knockout mice. J Biol Chem. 2014;289:20606–20614.
   PubMed Web of Science ®Google Scholar
• Upadhyay M, Agarwal S, Bhadauriya P, et al. Loss of laforin or malin results in increased Drp1 level and concomitant mitochondrial fragmentation in Lafora disease mouse models. Neurobiol Dis. 2017;100:39–51.
   PubMed Web of Science ®Google Scholar
• Puri R, Suzuki T, Yamakawa K, et al. Dysfunctions in endosomal-lysosomal and autophagy pathways underlie neuropathology in a mouse model for Lafora disease. Hum Mol Genet. 2012;21:175–184.
   PubMed Web of Science ®Google Scholar
• Jain N, Mishra R, Ganesh S. FoxO3a-mediated autophagy is down-regulated in the laforin deficient mice, an animal model for Lafora progressive myoclonus epilepsy. Biochem Biophys Res Commun. 2016;474:321–327.
   PubMed Web of Science ®Google Scholar
• Mittal S, Dubey D, Yamakawa K, et al. Lafora disease proteins malin and laforin are recruited to aggresomes in response to proteasomal impairment. Hum Mol Genet. 2007;16:753–762.
   PubMed Web of Science ®Google Scholar
• Singh PK, Singh S, Ganesh S. The laforin-malin complex negatively regulates glycogen synthesis by modulating cellular glucose uptake via glucose transporters. Mol Cell Biol. 2012;32:652–663.
   PubMed Web of Science ®Google Scholar
• Dienel GA, Cruz NF. Contributions of glycogen to astrocytic energetics during brain activation. Metab Brain Dis. 2015;30:281–298.
   PubMed Web of Science ®Google Scholar
• DiNuzzo M, Mangia S, Maraviglia B, et al. Does abnormal glycogen structure contribute to increased susceptibility to seizures in epilepsy? Metab Brain Dis. 2015;30:307–316.
   PubMed Web of Science ®Google Scholar
• López-Ramos JC, Duran J, Gruart A, et al. Role of brain glycogen in the response to hypoxia and in susceptibility to epilepsy. Front Cell Neurosci. 2015;9:431.
   PubMed Web of Science ®Google Scholar
• Rai A, Singh PK, Singh V, et al. Glycogen synthase protects neurons from cytotoxicity of mutant huntingtin by enhancing the autophagy flux. Cell Death Dis. 2018;9:201.
   PubMed Web of Science ®Google Scholar
• Andrade DM, Ackerley CA, Minett TS, et al. Skin biopsy in Lafora disease: genotype-phenotype correlations and diagnostic pitfalls. Neurology. 2003;61:611–614.
   Web of Science ®Google Scholar
• Kollmann K, Uusi-Rauva K, Scifo E, et al. Cell biology and function of neuronal ceroid lipofuscinosis-related proteins. BBA-Molecular Basis of Disease. 2013;1832:1866–1881.
   PubMed Web of Science ®Google Scholar
• Nita DA, Mole SE, Minassian BA. Neuronal ceroid lipofuscinoses. Epileptic Disord. 2016;18:S73–S88.
   PubMed Web of Science ®Google Scholar
• Stengel OC. Beretnig om et maerkeligt Sygdomstilfaelde hos fire Sødskende I Nærheden af Roraas. Eyr. 1826;1:347–352.
   Google Scholar
• Mole SE, Cotman SL. Genetics of the neuronal ceroid lipofuscinoses (Batten disease). BBA-Molecular Basis of Disease. 2015;1852:2237–2241.
   PubMed Web of Science ®Google Scholar
• Cárcel-Trullols J, Kovács AD, Pearce DA. Cell biology of the NCL proteins: what they do and don’t do. BBA-Molecular Basis of Disease. 2015;1852:2242–2255.
   PubMed Web of Science ®Google Scholar
• Koskiniemi M, Donner M, Majuri H, et al. Progressive myoclonus epilepsy. A clinical and histopathological study. Acta Neurol Scand. 1974;50:307–332.
   PubMed Web of Science ®Google Scholar
• Koskiniemi M, Toivakka E, Donner M. Progressive myoclonus epilepsy. Electroencephalographical findings. Acta Neurol Scand. 1974;50:333–359.
   PubMed Web of Science ®Google Scholar
• Mascalchi M, Michelucci R, Cosottini M, et al. Brainstem involvement in Unverricht-Lundborg disease (EPM1): an MRI and (1)H MRS study. Neurology. 2002;58:1686–1689.
   PubMed Web of Science ®Google Scholar
• Koskenkorva P, Khyuppenen J, Niskanen E, et al. Bilateral atrophy of the motor cortex and thalami in Unverricht-Lundborg disease: a voxel-based morphometric study. Neurology. 2009;73:606–611.
   PubMed Web of Science ®Google Scholar
• Magaudda A, Ferlazzo E, Nguyen VH, et al. Unverricht-Lundborg disease, a condition with self-limited progression: long-term follow-up of 20 patients. Epilepsia. 2006;47:860–866.
   PubMed Web of Science ®Google Scholar
• Canafoglia L, Ciano C, Visani E, et al. Short and long interval cortical inhibition in patients with Unverricht-Lundborg and Lafora body disease. Epilepsy Res. 2010;89:232–237.
   PubMed Web of Science ®Google Scholar
• Striano P, Zara F, Turnbull J, et al. Typical progression of myoclonic epilepsy of the Lafora type, a case report. Nat Clin Pract Neurol. 2008;4:106–111.
   PubMedGoogle Scholar
• Ganesh S, Puri R, Singh S, et al. Recent advances in the molecular basis of Lafora’s progressive myoclonus epilepsy. J Hum Genet. 2006;51:1–8.
   PubMed Web of Science ®Google Scholar
• Kohlschütter A, Schulz A, Denecke J. Epilepsy in neuronal ceroid lipofuscinoses. J Pediatr Epilepsy. 2014;3:199–206.
   Google Scholar
• Minassian BA. The progressive myoclonus epilepsies. Prog Brain Res. 2014;213:113–122.
   PubMed Web of Science ®Google Scholar
• Jalanko A, Braulke T. Neuronal ceroid lipofuscinoses. BBA-Molecular Res. 2009;1793:697–699.
   PubMed Web of Science ®Google Scholar
• Magrinelli F, Pezzini F, Moro F, et al. Diagnostic methods and emerging treatments for adult neuronal ceroid lipofuscinoses (Kufs disease). Expert Opin Orphan Drugs. 2017;5:487–501.
   Web of Science ®Google Scholar
• Ç Ö, Gündüz A, Coşkun T, et al. Long-term follow-up of two siblings with adult-onset neuronal ceroid lipofuscinosis, Kufs type A. Epileptic Disord. 2017;19:147–151.
   PubMed Web of Science ®Google Scholar
• Anderson GW, Goebel HH, Simonati A. Human pathology in NCL. BBA Molecular Basis Disease. 2013;1832:1807–1826.
   PubMed Web of Science ®Google Scholar
• Siintola E, Partanen S, Strömme P, et al. Cathepsin D deficiency underlies congenital human neuronal ceroid-lipofuscinosis. Brain. 2006;129:1438–1445.
   PubMed Web of Science ®Google Scholar
• Di Fabio R, Colonnese C, Santorelli FM, et al. Brain imaging in Kufs disease type B. BMC Neurol. 2015;15:102.
   PubMed Web of Science ®Google Scholar
• Mancuso M, Orsucci D, Angelini C et al. Phenotypic heterogeneity of the 8344A> G mtDNA “MERRF” mutation. Neurology. 2013;80:2049–2054.
   PubMed Web of Science ®Google Scholar
• Lamperti C, Zeviani M. Myoclonus epilepsy in mitochondrial disorders. Epileptic Disord. 2016;18:S94–102.
   PubMed Web of Science ®Google Scholar
• DiMauro S, Hirano M, Kaufmann P, et al. Clinical features and genetics of myoclonic epilepsy with ragged red fibers. Adv Neurol. 2002;89:217–229.
   PubMedGoogle Scholar
• Rapin I, Goldfischer S, Katzman R, et al. The cherry-red spot-myoclonus syndrome. Ann Neurol. 1978;3:234–242.
   PubMed Web of Science ®Google Scholar
• Tomiyasu H, Yoshii F, Ohnuki Y, et al. The brainstem and thalamic lesions in dentatorubral pallidoluysian atrophy: an MRI study. Neurology. 1998;50:1887–1890.
   PubMed Web of Science ®Google Scholar
• Sugiyama A, Sato N, Nakata Y, et al. Clinical and magnetic resonance imaging features of elderly onset dentatorubral–pallidoluysian atrophy. J Neurol. 2018;265:322–329.
   PubMed Web of Science ®Google Scholar
• Lehesjoki AE, Gardiner M. Progressive myoclonus epilepsy: unverricht-Lundborg disease and neuronal ceroid lipofuscinoses. In: editor, Noebels JL, Avoli M, Rogawski MA, et al. Jasper’s basic mechanisms of the epilepsies [Internet]. 4th ed. Bethesda (MD): National Center for Biotechnology Information (US); 2012.
   Google Scholar
• Haltia M, Goebel HH. The neuronal ceroid-lipofuscinoses: a historical introduction. Biochim Biophys Acta. 2013;1832:1795–1800.
   PubMed Web of Science ®Google Scholar
• Schulz A, Kohlschütter A, Mink J, et al. NCL diseases—clinical perspectives. BBA-Molecular Basis of Disease. 2013;1832:1801–1806.
   PubMed Web of Science ®Google Scholar
• Liu Y, Yi F, Kumar AB, et al. Multiplex tandem mass spectrometry enzymatic activity assay for newborn screening of the mucopolysaccharidoses and type 2 neuronal ceroid lipofuscinosis. Clin Chem. 2017;63:1118–1126.
   PubMed Web of Science ®Google Scholar
• DiMauro S, Michio H. M, Adam MP, et al. editors. GeneReviews® [Internet]. Seattle (WA): University of Washington; 2004 Jun 24 [Updated 2014 Nov 26]. p. 1993–2018.
   Google Scholar
• Rosing HS, Hopkins LC, Wallace DC, et al. Maternally inherited mitochondrial myopathy and myoclonic epilepsy. Ann Neurol. 1985;17:228–237.
   PubMed Web of Science ®Google Scholar
• Berkovic SF, Shoubridge EA, Andermann F, et al. Clinical spectrum of mitochondrial DNA mutation at base pair 8344. Lancet. 1991;338:457.
   PubMed Web of Science ®Google Scholar
• Wallace DC, Zheng X, Lott MT, et al. Familial mitochondrial encephalomyopathy (MERRF): genetic, pathophysiological, and biochemical characterization of a mitochondrial DNA disease. Cell. 1988;55:601–610.
   PubMed Web of Science ®Google Scholar
• Chomyn A, Meola G, Bresolin N, et al. In vitro genetic transfer of protein synthesis and respiration defects to mitochondrial DNA-less cells with myopathy-patient mitochondria. Mol Cell Biol. 1991;11:2236–2244.
   PubMed Web of Science ®Google Scholar
• Folbergrová J, Kunz WS. Mitochondrial dysfunction in epilepsy. Mitochondrion. 2012;12:35–40.
   PubMed Web of Science ®Google Scholar
• Lorenzoni PJ, Scola RH, Kay CS, et al. When should MERRF (myoclonus epilepsy associated with ragged-red fibers) be the diagnosis? Arq Neuropsiquiatr. 2014;72:803–811.
   PubMed Web of Science ®Google Scholar
• Mancuso M, Petrozzi L, Filosto M, et al. MERRF syndrome without ragged-red fibers: the need for molecular diagnosis.”. Biochem Biophys Res Commun. 2007;354:1058–1060.
   PubMed Web of Science ®Google Scholar
• Durand P, Gatti R, Cavalieri S, et al. Sialidosis (mucolipidosis I). Helv Paediatr Acta. 1977;32:391–400.
   PubMedGoogle Scholar
• Franceschetti S, Canafoglia L. Sialidoses. Epileptic Disord. 2016;18:89–93.
   PubMed Web of Science ®Google Scholar
• Bonten EJ, Arts WF, Beck M, et al. Novel mutations in lysosomal neuraminidase identify functional domains and determine clinical severity in sialidosis. Hum Mol Genet. 2000;9:2715–2725.
   PubMed Web of Science ®Google Scholar
• Buchholz T, Molitor G, Lukong KE, et al. Clinical presentation of congenital sialidosis in a patient with a neuraminidase gene frameshift mutation. Eur J Pediatr. 2001;160:26–30.
   PubMed Web of Science ®Google Scholar
• d’Azzo A, Machado E, Annunziata I. Pathogenesis, emerging therapeutic targets and treatment in sialidosis. Expert Opin Orphan Drugs. 2015;3:491–494.
   PubMed Web of Science ®Google Scholar
• Lukong KE, Landry K, Elsliger MA, et al. Mutations in sialidosis impair sialidase binding to the lysosomal multienzyme complex. J Biol Chem. 2001;276:17286–17290.
   PubMed Web of Science ®Google Scholar
• De Geest N, Bonten E, Mann L, et al. Systemic and neurologic abnormalities distinguish the lysosomal disorders sialidosis and galactosialidosis in mice. Hum Mol Genet. 2002;11:1455–1464.
   PubMed Web of Science ®Google Scholar
• Bonten EJ, Yogalingam G, Hu H, et al. Chaperone-mediated gene therapy with recombinant AAV-PPCA in a new mouse model of type I sialidosis. Biochim Biophys Acta. 2013;1832:1784–1792.
   PubMed Web of Science ®Google Scholar
• Wang IH, Lin TY, Kao ST. Optical coherence tomography features in a case of Type I sialidosis. Taiwan J Ophthalmol. 2017;7:108–111.
   PubMedGoogle Scholar
• Canafoglia L, Franceschetti S, Uziel G, et al. Characterization of severe action myoclonus in sialidoses. Epilepsy Res. 2011;94:86–93.
   PubMed Web of Science ®Google Scholar
• Koide R, Ikeuchi T, Onodera O, et al. Unstable expansion of CAG repeat in hereditary dentatorubral–pallidoluysian atrophy (DRPLA). Nat Genet. 1994;6:9–13.
   PubMed Web of Science ®Google Scholar
• Yamada M. Dentatorubral-pallidoluysian atrophy (DRPLA). Neuropathology. 2010;30:453–457.
   PubMed Web of Science ®Google Scholar
• Wardle M, Morris HR, Robertson NP. Clinical and genetic characteristics of non-Asian dentatorubral–pallidoluysian atrophy: a systematic review. Mov Disord. 2009;24:1636–1640.
   PubMed Web of Science ®Google Scholar
• Nagafuchi S, Yanagisawa H, Ohsaki E, et al. Structure and expression of the gene responsible for the triplet repeat disorder, dentatorubral and pallidoluysian atrophy (DRPLA). Nature Genet. 1994;8:177–182.
   PubMed Web of Science ®Google Scholar
• Veneziano L, Frontali M. DRPLA. GeneReviews. In: Adam MP, Ardinger HH, Pagon RA, et al. editors. GeneReviews® [Internet]. Seattle (WA): University of Washington; 2004 Jun 24 [Updated 2016 Nov 26]. p. 1993–2018.
   Google Scholar
• Suzuki Y, Nakayama K, Hashimoto N, et al. Proteolytic processing regulates pathological accumulation in dentatorubral-pallidoluysian atrophy. FEBS J. 2010;277:4873–4887.
   PubMed Web of Science ®Google Scholar
• Yamada M, Tsuji S, Takahashi H. Pathology of CAG repeat diseases. Neuropathology. 2000;20:319–325.
   PubMed Web of Science ®Google Scholar
• Hatano K, Ishiura H, Date H, et al. Search for target genes of transcriptional regulation by Dentatorubral-pallidoluysian atrophy protein that acts as a transcriptional co-regulator. J Neurol Sci. 2017;381:57.
   Web of Science ®Google Scholar
• Ahmad K, Baig MH, Gupta GK, et al. Identification of common therapeutic targets for selected neurodegenerative disorders: an in silico approach. J Comput Sci. 2016;17:292–296.
   Web of Science ®Google Scholar
• Tunc S, Tadic V, Zühlke C, et al. Pearls & Oy-sters: family history of Huntington disease disguised a case of dentatorubral-pallidoluysian atrophy. Neurology. 2018;90:142–143.
   PubMed Web of Science ®Google Scholar
• Iivanainen M, Himberg JJ. Valproate and clonazepam in the treatment of severe progressive myoclonus epilepsy. Arch Neurol. 1982;39:236–238.
   PubMedGoogle Scholar
• Chowdhury A, Brodie MJ. Pharmacological outcomes in juvenile myoclonic epilepsy: support for sodium valproate. Epilepsy Res. 2016;119:62–66.
   PubMed Web of Science ®Google Scholar
• Ferlazzo E, Trenite DK, De Haan GJ, et al. Update on pharmacological treatment of progressive myoclonus epilepsies. Curr Pharm Des. 2017;23:5662–5666.
   PubMed Web of Science ®Google Scholar
• Lam CW, Lau CH, Williams JC, et al. Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) triggered by valproate therapy. Eur J Pediatr. 1997;156:562–564.
   PubMed Web of Science ®Google Scholar
• Tein I, DiMauro S, Xie ZW, et al. Valproic acid impairs carnitine uptake in cultured human skin fibroblasts. an in vitro model for the pathogenesis of valproic acid–associated carnitine deficiency. Pediatr Res. 1993;34:281–287.
   PubMed Web of Science ®Google Scholar
• Bromley RL, Calderbank R, Cheyne CP, et al. Cognition in school-age children exposed to levetiracetam, topiramate, or sodium valproate. Neurology. 2016;87:1943–1953.
   PubMed Web of Science ®Google Scholar
• Nanda RN, Johnson RH, Keogh HJ, et al. Treatment of epilepsy with clonazepam and its effect on other anticonvulsants. J Neurol Neurosurg Psychiatry. 1977;40:538–543.
   PubMed Web of Science ®Google Scholar
• Michelucci R, Pasini E, Riguzzi P, et al. Myoclonus and seizures in progressive myoclonus epilepsies: pharmacology and therapeutic trials. Epileptic Disorders. 2016;18:S145–S153.
   PubMed Web of Science ®Google Scholar
• Brown P, Steiger MJ, Thompson PD, et al. Effectiveness of piracetam in cortical myoclonus. Mov Disord. 1993;8:63–68.
   PubMed Web of Science ®Google Scholar
• Koskiniemi M, Van Vleymen B, Hakamies L, et al. Piracetam relieves symptoms in progressive myoclonus epilepsy: a multicentre, randomized, double blind, crossover study comparing the efficacy and safety of three dosages of oral piracetam vs placebo. J Neurol Neurosurg Psychiatry. 1998;64:344–348.
   PubMed Web of Science ®Google Scholar
• Fedi M, Reutens D, Dubeau F, et al. Long-term efficacy and safety of piracetam in the treatment of progressive myoclonus epilepsies. Arch Neurol. 2001;58:781–786.
   PubMedGoogle Scholar
• Magaudda A, Gelisse P, Genton P. Antimyoclonic effect of levetiracetam in 13 patients with Unverricht–lundborg disease: clinical observations. Epilepsia. 2004;45:678–681.
   PubMed Web of Science ®Google Scholar
• Klein P, Diaz A, Gasalla T, et al. A review of the pharmacology and clinical efficacy of brivaracetam. Clin Pharmacol. 2018;10:1–22.
   PubMed Web of Science ®Google Scholar
• Rogawski MA. AMPA receptors as a molecular target in epilepsy therapy. Acta Neurol Scand Suppl. 2013;197:9–18.
   Google Scholar
• Aykutlu E, Baykan B, Gürses C, et al. Add-on therapy with topiramate in progressive myoclonic epilepsy. Epilepsy Behav. 2005;6:260–263.
   PubMed Web of Science ®Google Scholar
• Vossler DG, Conry JA, Murphy JV, et al. Zonisamide for the treatment of myoclonic seizures in progressive myoclonus epilepsy: an open label study. Epileptic Disord. 2008;10:31–34.
   PubMed Web of Science ®Google Scholar
• Italiano D, Pezzella M, Coppola A, et al. A pilot open-label trial of zonisamide in Unverricht-Lundborg disease. Mov Disord. 2011;26:341–343.
   PubMed Web of Science ®Google Scholar
• Tsai JJ, Wu T, Leung H, et al. Perampanel, an AMPA receptor antagonist: from clinical research to practice in clinical settings. Acta Neurol Scand. 2018;137:378–391.
   PubMed Web of Science ®Google Scholar
• Goldsmith D, Minassian BA. Efficacy and tolerability of perampanel in ten patients with Lafora disease. Epilepsy Behav. 2016;62:132–135.
   PubMed Web of Science ®Google Scholar
• Shiraishi H, Egawa K, Ito T, et al. Efficacy of perampanel for controlling seizures and improving neurological dysfunction in a patient with dentatorubral-pallidoluysian atrophy (DRPLA). Epilepsy Behav Case Rep. 2017;8:44–46.
   PubMed Web of Science ®Google Scholar
• Faulkner MA. Spotlight on perampanel in the management of seizures: design, development and an update on place in therapy. Drug Des Devel Ther. 2017;11:2921–2930.
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Yuen AW. Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 Study Group. Epilepsy Res. 1997;26:423–432.
   PubMed Web of Science ®Google Scholar
• Miyahara A, Saito Y, Sugai K, et al. Reassessment of phenytoin for treatment of late stage progressive myoclonus epilepsy complicated with status epilepticus. Epilepsy Res. 2009;84:201–209.
   PubMed Web of Science ®Google Scholar
• Sánchez-Elexpuru G, Serratosa JM, Sanz P, et al. 4-Phenylbutyric acid and metformin decrease sensitivity to pentylenetetrazol-induced seizures in a malin knockout model of Lafora disease. NeuroReport. 2017;28:268–271.
   PubMed Web of Science ®Google Scholar
• Tomson T, Battino D, Bonizzoni E, et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol. 2018;17:530–538.
   PubMed Web of Science ®Google Scholar
• Hurd RW, Wilder BJ, Helveston WR, et al. Treatment of four siblings with progressive myoclonus epilepsy of the Unverricht-Lundborg type with N acetylcysteine. Neurology. 1996;47:1264–1268.
   PubMed Web of Science ®Google Scholar
• Sánchez‐Elexpuru G, Serratosa JM, Sánchez MP. Sodium selenate treatment improves symptoms and seizure susceptibility in a malin-deficient mouse model of Lafora disease. Epilepsia. 2017;58:467–475.
   PubMed Web of Science ®Google Scholar
• Strzelczyk A, Reif PS, Bauer S, et al. Intravenous initiation and maintenance of ketogenic diet: proof of concept in super-refractory status epilepticus. Seizure. 2013;22:581–583.
   PubMed Web of Science ®Google Scholar
• Geraets RD, Yon Koh S, Ml H, et al. Moving towards effective therapeutic strategies for Neuronal Ceroid Lipofuscinosis. Orphanet J Rare Dis. 2016;11:40.
   PubMed Web of Science ®Google Scholar
• Hajnsek S, Gadze ZP, Borovecki F, et al. Vagus nerve stimulation in Lafora body disease. Epilepsy Behav Case Rep. 2013;1:150–152.
   PubMedGoogle Scholar
• Sebastiano DR, Magaudda A, Quartarone A, et al. Effect of repetitive transcranial magnetic stimulation on action myoclonus: a pilot study in patients with EPM1. Epilepsy Behav. 2018;80:33–36.
   PubMed Web of Science ®Google Scholar
• Minassian BA. Post-modern therapeutic approaches for progressive myoclonus epilepsy. Epileptic Disord. 2016;18:S154–S158.
   PubMed Web of Science ®Google Scholar
• Mizushima N, Komatsu M. Autophagy: renovation of cells and tissues. Cell. 2011;147:728–741.
   PubMed Web of Science ®Google Scholar
• Aguado C, Sarkar S, Korolchuk VI, et al. Laforin, the most common protein mutated in Lafora disease, regulates autophagy. Hum Mol Genet. 2010;19:2867–2876.
   PubMed Web of Science ®Google Scholar
• Singh PK, Singh S, Ganesh S. Activation of serum/glucocorticoid-induced kinase 1 (SGK1) underlies increased glycogen levels, mTOR activation, and autophagy defects in Lafora disease. Mol Biol Cell. 2013;24:3776–3786.
   PubMed Web of Science ®Google Scholar
• Seranova E, Connolly KJ, Zatyka M, et al. Dysregulation of autophagy as a common mechanism in lysosomal storage diseases. Essays Biochem. 2017;61:733–749.
   PubMed Web of Science ®Google Scholar
• Seino J, Wang L, Harada Y, et al. Basal autophagy is required for the efficient catabolism of sialyloligosaccharides. J Biol Chem. 2013;288:26898–26907.
   PubMed Web of Science ®Google Scholar
• Settembre C, Di Malta C, Polito VA, et al. TFEB links autophagy to lysosomal biogenesis. Science. 2011;332:1429–1433.
   PubMed Web of Science ®Google Scholar
• Baron O, Boudi A, Dias C, et al. Stall in canonical autophagy-lysosome pathways prompts nucleophagy-based nuclear breakdown in neurodegeneration. Curr Biol. 2017;27:3626–3642.
   PubMed Web of Science ®Google Scholar
• Yuan JH, Sakiyama Y, Higuchi I, et al. Mitochondrial myopathy with autophagic vacuoles in patients with the m. 8344A> G mutation. J Clin Pathol. 2013;66:659–664.
   PubMed Web of Science ®Google Scholar
• Zlotogora J, Grotto I, Kaliner E, et al. The Israeli national population program of genetic carrier screening for reproductive purposes. Genet Med. 2015;18:203–206.
   PubMed Web of Science ®Google Scholar
• Karczewski KJ, Snyder MP. Integrative omics for health and disease. Nat Rev Genet. 2018;19:299–310.
   PubMed Web of Science ®Google Scholar